AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02353923 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: OcuStem Supplementation
Description: 2800 mg daily dosage of OcuStem, 2 capsules BID.
Study NCT01146236 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sutures
Description: Orthopedic surgical wounds closed with sutures
Study NCT01146236 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Staples
Description: Orthopedic surgical wounds closed with metallic staples
Study NCT02459574 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: AVATAR-AF ablation
Description: Experimental ablation protocol
Study NCT02459574 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-Arrhythmic therapy
Description: Group 2 will be prescribed medication listed below:~Amiodarone; Dronaderone; Sotalol Beta blockers; Calcium channel blockers; Flecainide; or Propafenone.~You will then be discharged from clinic. A research nurse will contact you by phone to make sure there are no problems and can make hospital appointments if needed.
Study NCT02459574 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional AF ablation
Description: Conventional ablation procedure
Study NCT02911779 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: change of medilateral angle line during crowning of the head
Description: change of medilateral angle line during crowning of the head
Study NCT00466856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: octreotide acetate
Description: Lung/liver Ratio Dose of SIR-Spheres~* \<10% Administer full dose of SIR-Spheres~* 10% to 15% Reduce dose of SIR-Spheres by 20%~* 16% to 20% Reduce dose of SIR-Spheres by 40%~* >20% Do not give SIR-Spheres
Study NCT00466856 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: yttrium Y 90 resin microspheres
Description: radiation
Study NCT03156517 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Deep Brain Stimulation
Study NCT01271933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pregabalin
Description: controlled release tablet; 165-495 mg/day; given once daily
Study NCT01271933 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: matching placebo tablet; given once daily
Study NCT03690869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cemiplimab (monotherapy)
Description: To be administered intravenously as monotherapy in Phase 1
Study NCT03690869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cemiplimab (maintenance)
Description: To be administered intravenously in combination with radiation and then used as maintenance therapy
Study NCT03690869 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Conventional or hypofractionated
Description: Combined with cemiplimab IV administration
Study NCT03690869 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Re-irradiation
Description: Combined with cemiplimab IV administration
Study NCT01642771 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Fu/epirubicin/CTX following Docetaxel
Description: Cycle 1-3: Docetaxel i.v. 75mg/m2 (One cycle = 21 days); Cycle 4-6: Fluorouracil i.v. 500 mg/m2, Epirubicin i.v. 75 mg/m2, Cyclophosphamide i.v. 500 mg/m2 (One cycle = 21 days)
Study NCT01642771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel/capecitabine followed by XEC
Description: Cycle 1-3: Docetaxel i.v. 75 mg/m2, Capecitabine, p.o., 1000 mg/m2，b.i.d (take Capecitabine for 2 weeks and withdraw for 1 week) (One cycle = 21 days); Cycle 4-6: Capecitabine, i.v. 1000 mg/m2, b.i.d (take for 2 weeks and withdraw for 1 week),Epirubicin, i.v. 75 mg/m2, Cyclophosphamide, i.v. 500 mg/m2 (One cycle = 21 days)
Study NCT03023878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Blinatumomab monotherapy was supplied in single-use sterile glass injection vials and administered as an IV infusion.
Study NCT03023878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Investigator's Choice Chemotherapy
Description: During the run-in period participants received 6 cycles of standard of care rituximab-chemotherapy dosed per investigator's institution standard as follows:~* R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine,prednisone)~* R-DA-EPOCH (rituximab and dose adjusted-etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) or~* R-CHOEP (rituximab and cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide).
Study NCT03023878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 20 mg IV: within 1 hour prior to start of treatment in each treatment cycle, and within 1 hour prior to dose-step (increase).
Study NCT03962270 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: shock wave device
Description: The experimental group (group ESWT) guided by ultrasound: conventional rehabilitation training is given priority to with strength training, application of pain when necessary, under the guidance of ultrasound ESWT treatment control group (routine rehabilitation group) : conventional rehabilitation training is given priority to with strength training, oral pain when necessary, under the guidance of ultrasound ESWT treatment (shock energy flow density of 0)
Study NCT03962270 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: shock wave device
Description: The experimental group (group ESWT) guided by ultrasound: conventional rehabilitation training is given priority to with strength training, application of pain when necessary, under the guidance of ultrasound ESWT treatment control group (routine rehabilitation group) : conventional rehabilitation training is given priority to with strength training, oral pain when necessary, under the guidance of ultrasound ESWT treatment (shock energy flow density of 0)
Study NCT01198119 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Location of the suspected lesions
Description: The suspected lesions will be located before the excision, during the surgery.~1. With traditional light~2. NBI technique The images will be recorded and compared
Study NCT01198119 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: In case of suspected lesions detected by the NBI technique, this area is biopsied
Study NCT01198119 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lesion excision/Surgery
Description: In case of positive biopsy, the suspected lesions is excised
Study NCT03803085 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control condition
Description: Participants in the control group only saw their own daily walking steps using the WeChat. They did not use WeChat to see other group members' daily steps and did not contact other group members. The participants were asked to use the app every day. A message (through WeChat) was sent to remind them to use the application if they had not done so within three days.
Study NCT03803085 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment condition
Description: Participants in the experimental condition used WeChat for 4 weeks to see their own and other's walking steps and also were able to contact other group members. The participants were asked to use the application every day. A message (through the group chat) was sent to remind them to use the application if they have not done so within three days.
Study NCT01614613 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bayer G3 / Tatsu System
Description: Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with diabetes. All meter BG results were compared with plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
Study NCT01614613 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accu-Chek® Aviva Nano Meter/Accu-Chek® Aviva Test Strips
Description: Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with diabetes. All meter BG results were compared with plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
Study NCT01614613 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Freestyle Lite® Meter and Test Strips with ZipwikTM tabs
Description: Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with diabetes. All meter BG results were compared with plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
Study NCT01614613 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OneTouch® Ultra®2 / OneTouch® Ultra® Blue Test Strips
Description: Study staff performed Blood Glucose (BG) tested with capillary fingerstick blood collected from subjects with diabetes. All meter BG results were compared with plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
Study NCT01614613 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: One Touch® VerioTM Pro/One Touch® VerioTM Test Strips
Description: Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with diabetes. All meter BG results were compared with plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
Study NCT01614613 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Truetrack® Meter/Truetrack® Test Strips
Description: Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with diabetes. All meter BG results were compared with plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
Study NCT01725074 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Case Management CM CHD
Description: Patients, who are randomized to the intervention group, will receive case management from a trained and experienced physician assistant. The case manager will carry out following tasks:~* Biweekly/monthly telephone consultations or home visits~* Identification of health or personal problems of the patient~* Monitoring of medical parameters~* Coordination of contact with health care providers if necessary~* Support to the patient related to health status and environmental changes~* Promote disease-self management through coaching~* Counseling, that is focused on emotional support and active listening
Study NCT01725074 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Interaction
Description: Identical as the CM CHD group, but with exclusion of medical control measures and the medical aspects.
Study NCT02857374 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diagnostic Microscopy
Description: Undergo intravital microscopy
Study NCT02857374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorescein Sodium Injection
Description: Given IV
Study NCT02857374 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02857374 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sentinel Lymph Node Biopsy
Description: Undergo standard of care sentinel node biopsy
Study NCT04582097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramipril
Description: angiotensin-converting enzyme inhibitor
Study NCT04582097 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: same odor, color and size as the drug but without the active ingredient
Study NCT02100566 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling (Care giver burden focus)
Description: An advance directive (AD) document is provided to the patient along with counseling that focuses on care giver burden as the reason for adoption of the AD.
Study NCT02100566 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling (patient autonomy focus)
Description: An advance directive (AD) document is provided to the patient along with counseling that focuses on patient autonomy (control) as the reason for adoption of the AD.
Study NCT04133480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GWP42003-P
Description: oral solution of 100 milligrams per milliliter (mg/mL) cannabidiol (CBD)
Study NCT03148288 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: VItamin D
Study NCT03148288 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT01026688 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Toolkit
Description: Cardiovascular Disease Toolkit mailed by the Canadian Diabetes Association to family physicians, accompanying the Spring/Summer 2009 edition of the quarterly newsletter, Canadian Diabetes. (Mailed in June 2009.) The Toolkit includes a summary of selected sections of the practice guidelines targeted towards primary care physicians; a synopsis of the key messages pertaining to cardiovascular disease risk; a laminated card with a simplified algorithm for cardiovascular risk assessment and treatment; and a pad of tear-off sheets for patients with a cardiovascular risk self-assessment tool.
Study NCT01026688 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: The Spring/Summer 2009 issue of the quarterly newsletter, Canadian Diabetes, mailed on its own. The Cardiovascular Toolkit was mailed to Control arm physicians with the May 2010 issue of the newsletter.
Study NCT04583488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intraperitoneal docetaxel
Description: Up to 3 dose levels of intraperitoneal docetaxel will be studied (25mg/m2, 35 mg/m2, 45 mg/m2).
Study NCT03182920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasmiditan
Description: Oral administration
Study NCT03182920 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration
Study NCT04607603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol Oral Product
Description: Cannabidiol is administered in capsules. Each capsule contains 200mg of CBD administered 3 times daily to a total of 600mg per die
Study NCT04607603 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered in capsules of identical appearance to CBD capsules in 3 doses per die
Study NCT03665571 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Receptor specific activation method
Description: NK cell was incubated with P815-ULBP1+CD48 cells that trigger NK cell synergy via NKG2D and 2B4
Study NCT03594877 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sublimated mare milk
Description: The dietary supplement mare milk product, which is obtained from fresh (few hours) through sublimation process. This product is first mixed with warm water (37-38 degrees of Celsius) and then will be given to participants.
Study NCT01482871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALG-1001
Description: 1.5 mg per 100ul injected in the eye on day 0, day 30 and day 60 and followed for 180 days until unacceptable toxicity develops
Study NCT03197805 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PAM 50 test
Description: Patients with an equivocal-HER2 breast cancer (IHC Score 2 and equivocal ISH defined as HER2/Chr17 ratio \<2 and 4 ≤HER2 gene number copy \< 6) will be eligible for RNA genomic test (PAM 50 test). The use of genomic test could help the oncologist to define the better therapeutic decision in a HER2 equivocal population.
Study NCT00095199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed 500 mg/m\^2 administered intravenously on Day 1 of 3 weeks cycle until disease progression or unacceptable toxicity for up to six (3-week) cycles.
Study NCT00095199 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Pemetrexed 500 mg/m\^2 administered intravenously on Day 1 of 3 weeks cycle until disease progression or unacceptable toxicity for up to six (3-week) cycles.
Study NCT00095199 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab 400/250 mg/m\^2 (initial/weekly) administered intravenously on Days 1, 8, and 15 (3-week) cycles until disease progression or unacceptable toxicity.
Study NCT00095199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 75 mg/m\^2 administered intravenously on Day 1 of 3 weeks cycle until disease progression or unacceptable toxicity for up to six (3-week) cycles.
Study NCT00095199 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel 75 mg/m\^2 administered intravenously on Day 1 of 3 weeks cycle until disease progression or unacceptable toxicity for up to six (3-week) cycles.
Study NCT01999387 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Allergenic food
Study NCT02587156 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Meal serving at high dietary protein
Description: Participants are habituated to a high level of dietary protein intake for 21 days.
Study NCT02587156 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Meal serving at low dietary protein
Description: Participants are habituated to a low level of dietary protein intake for 21 days.
Study NCT02587156 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Meal serving
Description: To investigate impact of habituated protein level
Study NCT02587156 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Meal serving
Description: To investigate impact of habituated protein level
Study NCT00512187 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: low calorie diet
Description: Low calorie diet was designed to achieve a loss of 5-10% of initial weight. All enrolled patients received a balanced diet scheme, based on a caloric intake reduction related to BMI and sex (range 1200-1500 Kcal/day for women, 1300-1600 Kcal/day for men). Calorie intake consisted approximately of 60% carbohydrates, 25% fat, 15% protein
Study NCT04133571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.05% Lidocaine
Description: 0.05% lidocaine with normal saline as a bladder irrigation solution after transurethral surgery intravenous pethidine to decrease CRBD if needed
Study NCT03287479 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gavi® Vitrification
Description: A closed, semi-automated vitrification system
Study NCT03287479 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cryotop® Vitrification
Description: An open, manual vitrification system
Study NCT02100852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TGR-1202 + Obinutuzumab + Chlorambucil
Description: TGR-1202: Oral dose Obinutuzumab: IV infusion Chlorambucil: Oral dose
Study NCT00595660 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: FNA - fine needle aspiration
Description: Fine Needle aspiration
Study NCT00595660 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: FNA - fine needle aspiration
Description: Fine needle aspiration
Study NCT04506970 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Comprehensive Doppler Ultrasound of the Placenta
Description: Ultrasound measures to be collected include uterine artery (UtA) and umbilical artery (UA), systolic/diastolic (S/D) ratio, resistance index (RI), pulsatility index (PI) and presence of early diastolic notch.
Study NCT04506970 — intervention group
Intervention type: OTHER
Intervention: Verasonics Ultrasound scanner (ultra-sensitive Doppler imaging)
Description: In addition, a Verasonics ultrasound scanner will be used for ultra-sensitive Doppler imaging. Data will be collected on vessel density, periphery-to-center vessel density ratio (VDR) and microvessel morphology.
Study NCT03870763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimethyl Fumarate
Description: Administered as specified in the treatment arm.
Study NCT03870763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon Beta-1a
Description: Administered as specified in the treatment arm.
Study NCT03870763 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as specified in the treatment arm.
Study NCT00116805 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TDF
Description: 300 mg tablet administered orally once daily
Study NCT00116805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TDF
Description: 300 mg tablet administered orally once daily
Study NCT00116805 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ADV
Description: 10 mg tablet administered orally once daily
Study NCT00116805 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TDF placebo
Description: Tablet administered orally once daily
Study NCT00116805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADV placebo
Description: Tablet administered orally once daily
Study NCT00116805 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FTC/TDF
Description: 200/300 mg fixed-dose combination (FDC) tablet administered orally once daily
Study NCT00116805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTC/TDF
Description: 200/300 mg fixed-dose combination (FDC) tablet administered orally once daily
Study NCT01479660 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Placebo will be orally administered daily for a period of 12 weeks in high dose and low dose